G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11320%2F22%3A10445230" target="_blank" >RIV/00216208:11320/22:10445230 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/22:10445230 RIV/00064165:_____/22:10445230
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=BpF3D7EfXX" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=BpF3D7EfXX</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41408-022-00698-2" target="_blank" >10.1038/s41408-022-00698-2</a>

Result language
angličtina
Original language name
G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
Original language description
Academic, open label, randomized trial: G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome. GA trial is registered under EudraCT#: 2013-001639-38.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)